"Media Relations Contacts"
Contacts: Entelos, Inc. American Diabetes Association Allyson Zwahlen Diane Tuncer email@example.com firstname.lastname@example.org Tel: +1.650.572.5488 Tel: +1.703.549.1500 For immediate release: ADA Initiates Cutting-Edge Research Program to Prevent Type 1 Diabetes Entelos and ADA to Make In Silico Technology Available to Academic Researchers Orlando, FL June 5th, 2004 – The American Diabetes Association (ADA) today announced during a press briefing at the ADA’s 64th Scientific Sessions a collaboration with Entelos® Inc., to initiate a cutting-edge research program aimed at preventing type 1 diabetes. Entelos is a biotech company pioneering in silico (in computer) research and the use of computer models to advance pharmaceutical research and development. The ADA and Entelos will develop an in silico research platform based on a non-obese diabetic (NOD) mouse, the primary animal model used by researchers to study type 1 diabetes. The platform will initially be used by Entelos and certain academic research laboratories to address key scientific questions related to the onset and progression of this disease. The first academic centers to receive the technology will be those led by members of the ADA’s type 1 diabetes Scientific Advisory Board, which has been formed to provide scientific guidance and oversight to the collaboration. Over time, the platform will also be made available to other academic researchers through the ADA’s grant process. It is anticipated that the improved scientific understanding gained through this effort will lead to therapies for the prevention of human type 1 diabetes. The Scientific Advisory Board consists of key thought leaders and researchers in the area of type 1 diabetes research and each member will contribute to the collaboration by providing advice and guidance to the development of the model. Members include Aldo Rossini, M.D. of University of Massachusetts and last year’s Banting medal winner; Jeff Bluestone, Ph.D. of University California San Francisco and Director of Immune Tolerance Network; George Eisenbarth, M.D., Ph.D. of University Colorado Health Science Center and Executive Director of Barbara Davis Center; Mark Atkinson, Ph.D. of University of Florida and this year’s OSAA winner; and Diane Mathis, Ph.D. of the Joslin Diabetes Center and Academy of Sciences member. Type 1 diabetes is an auto-immune disease that affects approximately one million people, most of them children, in the U.S. alone. The disease arises from the auto-immune destruction of islet -more- ADA Initiates Cutting-Edge Research Program…2 beta-cells in the pancreas, leading to the failure to produce insulin which causes a loss of glucose control. The current treatment for type 1 diabetes is the daily injection of insulin. Scientific understanding of this disease in humans has been limited by the difficulty of identifying those people likely to develop the disease as well as practical considerations in studying humans with the condition. At this time there are no preventative treatments available for human type 1 diabetes. Entelos' PhysioLab systems biology platforms employ sophisticated mathematical models to integrate information from diverse scientific and clinical sources to represent the complex and dynamic relationships within human biological networks. Dr. Richard Kahn, Ph.D., Chief Scientific and Medical Officer of ADA stated during the press briefing, “The first-generation NOD PhysioLab platform and the research that will follow from its use will help uncover the critical pathways that contribute to and regulate auto-immunity and cell destruction in type 1 diabetes. This will give us tremendous insight into the disease and aid in the identification and development of potential therapies to prevent its onset." Dr. Mikhail Gishizky, Ph.D., Chief Scientific Officer for Entelos, added, "Although numerous therapies have been shown to inhibit the development of type 1 diabetes in the NOD mouse, success in advancing these therapies to human patients has been limited. Through the use of predictive mathematical models, the research community will have a significant scientific advancement which will ultimately improve the rationale for taking novel interventions into humans.” Entelos, Inc. (www.entelos.com) is revolutionizing pharmaceutical R&D by employing disease level system biology technologies to identify and validate targets, biomarkers and compounds for human efficacy. Our breakthrough PhysioLab® systems biology platforms employ sophisticated mathematical models to integrate information from diverse scientific and clinical sources to represent the complex and dynamic relationships within human biological networks. Our primary mission is to increase the efficiency of pharmaceutical research and development and to expedite proprietary human therapeutics to the market. We have multiple PhysioLab® platforms in immunology and metabolism and are currently developing new platforms in cardiovascular, CNS and oncology. The American Diabetes Association (www.diabetes.org) is the nation's leading nonprofit health organization providing diabetes research, information and advocacy. Founded in 1940, the American Diabetes Association conducts programs in all 50 states and the District of Columbia, reaching hundreds of communities. Entelos is a registered trademark of Entelos, Inc. PhysioLab is a trademark and service mark of Entelos, Inc. All other trademarks are the property of their registered owners.